CClinicalTrials.gg
TerminatedNCT03298022TNFUpdated Jan 5, 2024Results posted

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

A Phase 2 interventional study of ALTB-168 in Ulcerative Colitis, sponsored by AltruBio Inc.. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by AltruBio Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
As a consequence of operational difficulties at the clinical sites associated with the COVID-19 pandemic
Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or anti-integrin treatments.

Read the detailed description

This is a Phase II, open label, single arm, multiple dose proof of principle study to test the efficacy and safety of Neihulizumab in patients with moderate to severe active ulcerative colitis and who has failed or are intolerant to anti-TNFα and/or anti-integrin therapy. A minimum of 30 patients and a maximum of 40 will be recruited in 1 dosing group. For efficacy evaluation, the primary endpoint is the proportion of patients with clinical response, defined as ≥ 3- point reduction in MCS, a 30% or greater decrease from the baseline score, and with a 1-point or greater decrease of the rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1 at Week 12. Safety assessments will consist of evaluating physical examination, vital signs (blood pressure, heart rate, respiratory rate, body temperature and oxygen saturation), safety laboratory tests, adverse events and tolerability.

02

Conditions studied

  • Ulcerative Colitis

Keywords

  • Ulcerative Colitis
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients must provide written informed consent;
  2. Age 18-75 years;
  3. Diagnosis of UC ≥ 12 weeks prior to screening by full colonoscopy (i.e., ≥ 12 weeks after first diagnosis by a physician according to American College of Gastroenterology guidelines);
  4. Moderate-to-severe active UC, at time of screening, defined as:

    1. Mayo Clinic Score (MCS) of 6 points or higher, AND
    2. a centrally read MCS endoscopic subscore of grade 2 or higher, AND
    3. MCS rectal bleeding subscore of 1 point or higher, AND
    4. disease extending 15 cm or more from the anal verge;
  5. Stable doses of concomitant medications, including :

    1. Stable oral corticosteroids (i.e., ≤ 20 mg/day of prednisone, ≤ 9 mg/day of budesonide) ≥ 2 weeks before D1 dosing; Taper of oral corticosteroids per Investigator's discretion during the study is allowed;
    2. Stable oral 5-amyinosalicylic acid dose ≥ 2 weeks before D1 dosing;
    3. Stable immunosuppressant including azathioprine, mercaptopurine, or methotrexate ≥ 8 weeks before D1 dosing. Patients taking methotrexate also are advised to take folic acid 1 mg/day or equivalent if there is no contraindication;
    4. Stable doses of probiotics ≥ 2 weeks before D1 dosing;
    5. Stable anti-diarrheas ≥ 2 weeks before D1 dosing;
  6. Patients must have previously received anti-tumor necrosis factor alpha (anti- TNF alpha and/or anti-integrin therapy for UC and demonstrated an inadequate response, loss of response, or intolerance, and must have discontinued therapy ≥ 8 weeks before D1 dosing;
  7. Patients previously treated with cyclosporine or tacrolimus must have discontinued therapy ≥ 4 weeks before D1 dosing;
  8. Topical corticosteroids and topical 5-amyinosalicylic acid preparations must have been withdrawn ≥ 2 weeks before D1 dosing;
  9. Nonsteroidal anti-inflammatory drugs (NSAIDs) must have been discontinued ≥ 4 weeks before D1 dosing;
  10. Tofacitinib or other Janus kinase (JAK) inhibitors must have been discontinued ≥ 2 weeks before D1 dosing;
  11. Patients previously treated with tube feeding, defined formula diets, or parenteral alimentation/nutrition must have discontinued treatment 3 weeks before D1 dosing;
  12. Females with reproductive potential must have a negative pregnancy test result before enrollment. Men and women with reproductive potential have to be willing to use a highly effective method of contraception from study start to ≥ 3 months after the final dose of the study drug. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).

Exclusion criteria

Exclusion Criteria:

GI related exclusion criteria:

  1. Indeterminate colitis (Inflammatory bowel disease unclassified, IBD-U) or suspected Crohn's disease
  2. Any history of colectomy
  3. Presence of an ileostomy or colostomy
  4. A history or evidence of colonic mucosal dysplasia
  5. Short gut syndrome

    General health related exclusion criteria:

  6. Pregnant or lactating
  7. Inability to comply with study protocol in the opinion of the investigator
  8. History of dysplasia or malignancy in recent 5 years, except completely excised basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  9. Cirrhosis or active alcohol abuse per the judgement of investigator
  10. Poorly controlled diabetes (HbA1c > 8.0%)
  11. Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block
  12. Impaired renal function (calculated creatinine clearance \< 60 mL/min)
  13. Impaired hepatic function in the absence of diagnosis of primary sclerosing cholangitis, serum transaminase > 2.5x Upper Limit Normal (ULN), alkaline phosphatase > 2.5x ULN, or increased total bilirubin judged by the investigator to be clinically significant, or a diagnosis of primary sclerosing cholangitis, serum transaminases > 3x ULN, alkaline phosphatase > 3x ULN, or total bilirubin > 2.5x ULN judged by the investigator to be clinically significant
  14. Moderate to severe anemia (Hb \< 8g/dL)
  15. Thrombocytopenia (platelet count \< 75,000/uL)
  16. Evidence of current or previous clinically significant disease, medical condition or finding in the medical examination that in the opinion of the investigator, would compromise the safety of the patient or quality of the data
  17. Requiring parenteral corticosteroid treatment.
  18. Received any investigational product within 1 year.
  19. History of drug abuse according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria within 12 months prior to screening or positive drug screening tests.

    Infection related exclusion criteria:

  20. Human immune deficiency virus (HIV) infection or known HIV-related malignancy.
  21. Acute or chronic hepatitis B or C, or carrier status. Patients with anti-HBc Ab but with undetectable anti-HBs Ab should also be excluded.
  22. Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus
  23. Positive stool test for ova or parasites, positive stool culture for pathogens, or positive stool toxin assay for Clostridium difficile at screening. Patients with the positive stool toxin assay for C. difficile at screening could be rescreened if they are being treated for C. difficile and a repeat stool toxin assay at least 4 weeks after the completion of treatment is negative with no evidence of recurrence.
  24. Intestinal mucosa biopsy positive for cytomegalovirus (CMV) at screening.
  25. Positive screening test for latent Mycobacterium tuberculosis (TB) infection. Patients with a history of latent TB infection who received an appropriate and documented course of therapy can be included if the screening examination and a chest x-ray performed ≤ 3 months before screening revealed no evidence of current active infection. If a Quantiferon TB test is indeterminate, the test should be repeated, and if the result is again indeterminate, such patient should be excluded.
  26. History of any opportunistic infection ≤ 12 weeks before D1 dosing.
  27. Any current or recent (≤ 4 weeks before D1 dosing) symptoms/signs of infection.
  28. Received oral antibiotics ≤ 4 weeks before D1 dosing or intravenous antibiotics ≤ 8 weeks before D1 dosing.
  29. Received a live attenuated vaccine ≤ 4 weeks before D1 dosing.
  30. Neutropenia (absolute neutrophil count \< 1,500/uL).
  31. Lymphocytopenia (absolute lymphocyte count \< 500 /uL).
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ALTB-168

    intravenous doses of ALTB-168

    Biological: ALTB-168

Interventions

  • BiologicalALTB-168

    monoclonal antibody

    Also known as: Neihulizumab

05

What researchers measure

Primary outcomes

  1. The Proportion of Patients With Clinical Response at Week 12

    The clinical response is defined as a ≥ 3-point reduction in Mayo Clinic Score, a 30% or greater decrease from the baseline score, and with a 1-point or greater decrease of the rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1, The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

    Time frame: week 12

Secondary outcomes

  1. The Proportion of Patients With Clinical Response (mITT)

    The proportion of patients with clinical response defined as a ≥2-point decrease in partial MCS (pMCS), and with a 1 point or greater decrease of the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

    Time frame: weeks 6,16, 20 and 26

  2. The Proportion of Patients With Clinical Remission

    The number of patients with clinical remission, defined as MCS of 2 or lower (or pMCS of 1 or lower) and no subscore higher than 1. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

    Time frame: weeks 6,16, 20 and 26

  3. Flexible Sigmoidoscopy Subscore Changes From Baseline

    The mean (SD) observed flexible sigmoidoscopy subscore change from baseline (CFB). Baseline is defined as the last available assessment prior to the first administration of the study drug. The sigmoidoscopic improvement is defined as any decrease in Mayo Clinic Score (MCS) endoscopic subscore, at Weeks 12 and 26. MCS range is 1-3. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

    Time frame: Baseline, week 12- and week 26 after the first treatment

  4. The Number of Patients With Mucosal Healing

    The mucosal healing is defined as an absolute subscore for endoscopy of 0 or 1 The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

    Time frame: at 12- and 26-week after the first treatment

  5. Change of Histological Activity Grade From Baseline Using the Geboes System

    The number of patients with histological activity Geboes Score ≤ 3.1 (worst of both rectum and sigmoid colon). The original Geboes grade system is from Grade 0 to Grade 5. The following are the grades: Grade 0: Architectural changes Grade 1: Chronic inflammatory infiltrate Grade 2A: Eosinophils in lamina propria Grade 2B: Neutrophils in lamina propria Grade 3: Neutrophils in epithelium Grade 4:Crypt destruction Grade 5: Erosions and ulcerations

    Time frame: at 12- and 26-week after the first treatment

  6. The Number of Patients With Histological Healing

    The histological healing is defined as histological grade = 0

    Time frame: at 12- and 26-week after the first treatment

  7. Change of Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline

    Number of Participants with a Clinically Significant Difference in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline, to Week 12 and Week 26. The IBDQ is a questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in patients with the Inflammatory Bowel Disease (IBD). The IBDQ has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better HRQoL. A difference of 16 points from Baseline Assessment (Baseline Score) to Week 12, and Baseline Assessment (Baseline Score) to Week 26, is considered clinically significant. The outcome measure is assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 26. Patients who achieved the 16 point difference (improvement of the IBDQ score from the baseline indicating the Clinically Significant Difference) are included as responders to the treatment.

    Time frame: at 12- and 26-week after the first treatment

  8. The Number of Patients With Inflammatory IBDQ Response

    The Inflammatory Bowel Disease Questionnaire (IBDQ) has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better Health Related Quality of Life (HRQoL). A difference of 16 points from Baseline to Week 12 and Baseline to Week 26, is considered clinically significant. The outcome measure will be assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 26, to assess whether a response was seen.

    Time frame: at 12- and 26-week after the first treatment

Other outcomes

  1. CRP Changes From Baseline (CFB) (Exploratory)

    Change in biomarkers of CRP (C-reactive protein). C-reactive protein (CRP) is a biomarker produced by your liver in response to inflammation. Normal CRP value is below 1 mg/L. 1-3 mg/L is in the "yellow zone", indicating some inflammation \>3 mg/L is in the "red zone", meaning there is significant inflammation

    Time frame: Am 4, Weeks 4, 9, 12, 16, 20, 26; Am 1-3 weeks 4,8,12,16,20, 26

  2. Changes in Fecal Calprotectin (CFB) - Exploratory Biomarker

    Faecal calprotectin changes from the baseline at Week 4, 9, 12, 16, 20, and 26 were measured. Baseline is defined as the last available assessment prior to the first administration of the study drug. Faecal calprotectin is measured as mcg/g, so the results come back as a numeric value. A level under 50 is considered to be 'normal'. A level between 50 and 100, coupled with digestive symptoms, means IBS is likely. Lower level means improvement.

    Time frame: Am 4, Weeks 4, 9, 12, 16, 20, 26; Am 1-3 weeks 4,8,12,16,20, 26

06

Results

Posted Jul 6, 2023

Participant flow

Participants were enrolled at 12 centers locate in North America and Puerto Rico from May 2018 to June 2020. It was a 24 weeks open label, single arm, multiple dose proof of principle study.

Participant flow — Overall Study
MilestoneALTB-168 in Patients With Refractory Ulcerative Colitis
Started24
Number of participants who received 8 doses of altb-16810
Number of participants who received 10 doses of altb-16814
Completed11
Not completed13
Withdrew: Lack of efficacy4
Withdrew: Withdrawal by subject7
Withdrew: Adverse event1
Withdrew: Disease relapse1

Outcome measures

PrimaryThe Proportion of Patients With Clinical Response at Week 12

The clinical response is defined as a ≥ 3-point reduction in Mayo Clinic Score, a 30% or greater decrease from the baseline score, and with a 1-point or greater decrease of the rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1, The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

Time frame:
week 12
Reported as:
Number · percentage of total number of patients
The Proportion of Patients With Clinical Response at Week 12
percentage of total number of patientsPilot Study (Amendment 1~3: 9 mg/kg; Total 8 Doses)Main Study (Amendment 4: 9 mg/kg; Total 10 Doses)
The Proportion of Patients With Clinical Response at Week 1222.2 (2.8 to 60)50 (23 to 77)
SecondaryThe Proportion of Patients With Clinical Response (mITT)

The proportion of patients with clinical response defined as a ≥2-point decrease in partial MCS (pMCS), and with a 1 point or greater decrease of the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

Time frame:
weeks 6,16, 20 and 26
Reported as:
Number · percentage of total number of patients
The Proportion of Patients With Clinical Response (mITT)
percentage of total number of patientsPilot Study (Amendment 1~3: 9 mg/kg; Total 8 Doses)Main Study (Amendment 4: 9 mg/kg; Total 10 Doses)
Clinical Response at week 633.3 (7.5 to 70.1)57.1 (28.9 to 82.3)
Clinical Response at week 160 (0 to 0)64.3 (35.1 to 87.2)
Clinical Response at week 2011.1 (0.3 to 48.2)64.3 (35.1 to 87.2)
Clinical Response at week 2611.1 (0.3 to 48.2)35.7 (12.8 to 64.9)
SecondaryThe Proportion of Patients With Clinical Remission

The number of patients with clinical remission, defined as MCS of 2 or lower (or pMCS of 1 or lower) and no subscore higher than 1. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

Time frame:
weeks 6,16, 20 and 26
Reported as:
Number · percentage of total number of patients
The Proportion of Patients With Clinical Remission
percentage of total number of patientsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Clinical response at week 611.1 (0.3 to 48.2)35.7 (12.8 to 64.9)
Clinical response at week 160 (0 to 0)35.7 (12.8 to 64.9)
Clinical response at week 200 (0 to 0)35.7 (12.8 to 64.9)
Clinical response at week 2611.1 (0.3 to 48.2)21.4 (4.7 to 50.8)
SecondaryFlexible Sigmoidoscopy Subscore Changes From Baseline

The mean (SD) observed flexible sigmoidoscopy subscore change from baseline (CFB). Baseline is defined as the last available assessment prior to the first administration of the study drug. The sigmoidoscopic improvement is defined as any decrease in Mayo Clinic Score (MCS) endoscopic subscore, at Weeks 12 and 26. MCS range is 1-3. The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

Time frame:
Baseline, week 12- and week 26 after the first treatment
Reported as:
Mean · score on a scale
Flexible Sigmoidoscopy Subscore Changes From Baseline
score on a scaleAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Flexible Sigmoidoscopy Score at Baseline2.7 ± 0.52.6 ± 0.5
Flexible Sigmoidoscopy Score at week 12 CFB-0.7 ± 1.03-0.6 ± 1.0
Flexible Sigmoidoscopy Score at week 26 CFB0 ± 0-0.6 ± 1.27
SecondaryThe Number of Patients With Mucosal Healing

The mucosal healing is defined as an absolute subscore for endoscopy of 0 or 1 The colonic site with maximum inflammation was determined by Mayo endoscopic subscore (MES) defined as follows: normal (0 points); erythema, decreased vascular pattern, mild friability (1 point); absent vascular pattern, friability, erosions (2 points); and spontaneous bleeding or ulceration (3 points). Lower score means disease improvement.

Time frame:
at 12- and 26-week after the first treatment
Reported as:
Number · participants
The Number of Patients With Mucosal Healing
participantsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Week 1224
Week 2603
SecondaryChange of Histological Activity Grade From Baseline Using the Geboes System

The number of patients with histological activity Geboes Score ≤ 3.1 (worst of both rectum and sigmoid colon). The original Geboes grade system is from Grade 0 to Grade 5. The following are the grades: Grade 0: Architectural changes Grade 1: Chronic inflammatory infiltrate Grade 2A: Eosinophils in lamina propria Grade 2B: Neutrophils in lamina propria Grade 3: Neutrophils in epithelium Grade 4:Crypt destruction Grade 5: Erosions and ulcerations

Time frame:
at 12- and 26-week after the first treatment
Reported as:
Number · participants
Change of Histological Activity Grade From Baseline Using the Geboes System
participantsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Week 1202
Week 2614
SecondaryThe Number of Patients With Histological Healing

The histological healing is defined as histological grade = 0

Time frame:
at 12- and 26-week after the first treatment
Reported as:
Count of participants · Participants
The Number of Patients With Histological Healing
ParticipantsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Week 1200
Week 2600
SecondaryChange of Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline

Number of Participants with a Clinically Significant Difference in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline, to Week 12 and Week 26. The IBDQ is a questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in patients with the Inflammatory Bowel Disease (IBD). The IBDQ has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better HRQoL. A difference of 16 points from Baseline Assessment (Baseline Score) to Week 12, and Baseline Assessment (Baseline Score) to Week 26, is considered clinically significant. The outcome measure is assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 26. Patients who achieved the 16 point difference (improvement of the IBDQ score from the baseline indicating the Clinically Significant Difference) are included as responders to the treatment.

Time frame:
at 12- and 26-week after the first treatment
Reported as:
Number · participants
Change of Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline
participantsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Week 1229
Week 2617
SecondaryThe Number of Patients With Inflammatory IBDQ Response

The Inflammatory Bowel Disease Questionnaire (IBDQ) has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better Health Related Quality of Life (HRQoL). A difference of 16 points from Baseline to Week 12 and Baseline to Week 26, is considered clinically significant. The outcome measure will be assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 26, to assess whether a response was seen.

Time frame:
at 12- and 26-week after the first treatment
Reported as:
Number · participants
The Number of Patients With Inflammatory IBDQ Response
participantsAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Week 1229
Week 2617
Other pre-specifiedCRP Changes From Baseline (CFB) (Exploratory)

Change in biomarkers of CRP (C-reactive protein). C-reactive protein (CRP) is a biomarker produced by your liver in response to inflammation. Normal CRP value is below 1 mg/L. 1-3 mg/L is in the "yellow zone", indicating some inflammation \>3 mg/L is in the "red zone", meaning there is significant inflammation

Time frame:
Am 4, Weeks 4, 9, 12, 16, 20, 26; Am 1-3 weeks 4,8,12,16,20, 26
Reported as:
Mean · mg/L
CRP Changes From Baseline (CFB) (Exploratory)
mg/LAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Baseline4.3 ± 5.3211.29 ± 20.555
Week 46.5 ± 17.30-1.93 ± 14.403
Am 4 Week 9, Am 1-3 Week 86.2 ± 10.65-0.42 ± 18.821
Week 126.0 ± 8.490.12 ± 15.605
Week 16NA ± NA-0.65 ± 13.450
Week 20NA ± NA-2.94 ± 14.161
Week 26NA ± NA-0.42 ± 4.079
Other pre-specifiedChanges in Fecal Calprotectin (CFB) - Exploratory Biomarker

Faecal calprotectin changes from the baseline at Week 4, 9, 12, 16, 20, and 26 were measured. Baseline is defined as the last available assessment prior to the first administration of the study drug. Faecal calprotectin is measured as mcg/g, so the results come back as a numeric value. A level under 50 is considered to be 'normal'. A level between 50 and 100, coupled with digestive symptoms, means IBS is likely. Lower level means improvement.

Time frame:
Am 4, Weeks 4, 9, 12, 16, 20, 26; Am 1-3 weeks 4,8,12,16,20, 26
Reported as:
Mean · mcg/g
Changes in Fecal Calprotectin (CFB) - Exploratory Biomarker
mcg/gAmendment 1~3: 9 mg/kg; Total 8 DosesAmendment 4: 9 mg/kg; Total 10 Doses
Baseline682.80 ± 548.1531283.49 ± 758.019
Week 4 (CFB)113.89 ± 753.179-203.30 ± 704.559
Week 9 (Am 4, week 8 Am 1-3)223.17 ± 605.971-384.47 ± 662.420
Week 12923.00 ± 997.162-584.17 ± 847.809
Week 16NA ± NA-155.01 ± 1142.984
Week 20NA ± NA-29.46 ± 477.150
Week 26NA ± NA-780.30 ± 633.292

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALTB-168 9mg/kg (Amendment 1-3)0/10 (0%)1/10 (10%)9/10 (90%)
ALTB-168 9mg/kg (Amendment 4)0/14 (0%)0/14 (0%)13/14 (92.9%)
Most frequent serious events
Most frequent serious events
EventALTB-168 9mg/kg (Amendment 1-3)ALTB-168 9mg/kg (Amendment 4)
Ulcerative Colitis FlareGastrointestinal disorders1/100/14
Most frequent other events
Showing 10 of 31
Most frequent other events
EventALTB-168 9mg/kg (Amendment 1-3)ALTB-168 9mg/kg (Amendment 4)
HeadacheNervous system disorders5/105/14
Abdominal PainGastrointestinal disorders0/103/14
CoughRespiratory, thoracic and mediastinal disorders2/101/14
ConfusionInjury, poisoning and procedural complications0/102/14
Fecal Calprotectin IncreasedInvestigations0/102/14
RashSkin and subcutaneous tissue disorders0/102/14
NasopharyngitisInfections and infestations0/102/14
ConstipationGastrointestinal disorders1/100/14
ChillsGeneral disorders1/100/14
FatigueGeneral disorders1/100/14

Baseline characteristics

Safety population /The mITT set was defined as all patients who were enrolled and who received at least one dose of ALTB-168 treatment.

Age, Categorical
Age, Categorical(Participants)ALTB-168
Enrolled Under Amendment 1-3 — <=18 years0
Enrolled Under Amendment 1-3 — Between 18 and 65 years9
Enrolled Under Amendment 1-3 — >=65 years1
Enrolled Under Amendment 4 — <=18 years0
Enrolled Under Amendment 4 — Between 18 and 65 years14
Enrolled Under Amendment 4 — >=65 years0
Age, Continuous
Age, Continuous(years)ALTB-168
Amendment 1-337 (21 to 65)
Amendment 435.5 (22 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)ALTB-168
Enrolled under Amendment 1~3 — Female6
Enrolled under Amendment 1~3 — Male4
Enrolled under Amendment 4 — Female7
Enrolled under Amendment 4 — Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ALTB-168
Ethnicity — Hispanic or Latino7
Ethnicity — Not Hispanic or Latino15
Ethnicity — Not reported2
Region of Enrollment
Region of Enrollment(participants)ALTB-168
United States24
07

Study locations

12 sites
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72205, United States
  • Stomach Doctor - Surinder Saini, MD - Fountain Valley
    Newport Beach, California 92660, United States
  • Wellness Clinical Research (WCR)
    Hialeah, Florida 33016-2202, United States
  • Wellness Clinical Research (WCR)
    Lake Wales, Florida 33853, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Capitol Research
    Rockville, Maryland 20850, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Washington Medical Center (UWMC) - Digestive Disease Center
    Seattle, Washington 98195, United States
  • Wellness Clinical Research (WCR)
    Vega Baja, 00694, Puerto Rico
08

References and documents

Study documents

  • Study protocol · Nov 6, 2018
  • Statistical analysis plan · Oct 19, 2020
  • Informed consent form · Dec 13, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03298022
Lead sponsor
AltruBio Inc.
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
May 4, 2018
Primary completion
Apr 6, 2020
Completion
Jun 1, 2020
Results posted
Jul 6, 2023
Last update
Jan 5, 2024

Study contacts

Shih-Yao Lin, MD, PhD
study director · AltruBio Inc.
David T Rubin, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion